Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

BACKGROUND: Detecting epidermal growth factor receptor (EGFR) activating mutations in plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non-small cell lung cancer (NSCLC). However, dynamic quantitative changes of plasma EGFR mutations during the whole course of EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Yang, Jin-Ji, Chen, Zhi-Hong, Zhang, Xu-Chao, Yan, Hong-Hong, Xu, Chong-Rui, Su, Jian, Chen, Hua-Jun, Tu, Hai-Yan, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020532/
https://www.ncbi.nlm.nih.gov/pubmed/27619632
http://dx.doi.org/10.1186/s13045-016-0316-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020532/
https://www.ncbi.nlm.nih.gov/pubmed/27619632
http://dx.doi.org/10.1186/s13045-016-0316-8

Ejemplares similares